Melanoma tumor microbiome as a predictor of anti-PD-1 and anti-CTLA-4 immunotherapy response

被引：0
|
作者：
Uzelac, Matthew [1 ]
Li, Wei Tse [1 ]
Li, Yuxiang [1 ]
Ongkeko, Weg M. [1 ]
机构：
[1] Univ Calif San Diego, La Jolla, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14666
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Predictive biomarkers for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
    Subrahmanyam, Priyanka
    Dong, Zhiwan
    Gusenleitner, Daniel
    Giobbie-Hurder, Anita
    Severgnini, Mariano
    Zhou, Jun
    Manos, Michael
    Maecker, Holden
    Hodi, F. Stephen
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [2] CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients
    Goltz, Diane
    Gevensleben, Heidrun
    Vogt, Timo J.
    Dietrich, Joern
    Golletz, Carsten
    Bootz, Friedrich
    Kristiansen, Glen
    Landsberg, Jennifer
    Dietrich, Dimo
    [J]. JCI INSIGHT, 2018, 3 (13):
  • [3] Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
    Subrahmanyam, Priyanka B.
    Dong, Zhiwan
    Gusenleitner, Daniel
    Giobbie-Hurder, Anita
    Severgnini, Mariano
    Zhou, Jun
    Manos, Michael
    Eastman, Lauren M.
    Maecker, Holden T.
    Hodi, F. Stephen
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [4] Drug therapy of melanoma: anti-CTLA-4 and anti-PD-1 antibodies
    Robert, Caroline
    Mateus, Christina
    [J]. BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2014, 198 (02): : 297 - 308
  • [5] Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapy
    Rogiers, Aljosja
    Dimitriou, Florentia
    Lobon, Irene
    Harvey, Catriona
    Vergara, Ismael A.
    da Silva, Ines Pires
    Lo, Serigne N.
    Scolyer, Richard A.
    Carlino, Matteo S.
    Menzies, Alexander M.
    Long, Georgina V.
    [J]. EUROPEAN JOURNAL OF CANCER, 2024, 198
  • [6] Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma
    Reddy, Swathi B.
    Possick, Jennifer D.
    Kluger, Harriet M.
    Galan, Anjela
    Han, Dale
    [J]. JOURNAL OF IMMUNOTHERAPY, 2017, 40 (08) : 307 - 311
  • [7] Differences in immune profiles of metastatic melanoma patients treated with anti-CTLA-4 and anti-PD-1 combined immunotherapy.
    Gide, Tuba Nur
    Quek, Camelia
    Madore, Jason
    Menzies, Alexander M.
    Dent, Rebecca
    Carlino, Matteo S.
    Guminski, Alex
    Saw, Robyn
    Thompson, John F.
    Wilmott, James S.
    Scolyer, Richard A.
    Long, Georgina V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)
  • [8] Combination immunotherapy using anti-PD-1/PD-L1 plus anti-CTLA-4 antibodies
    Reck, Martin
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S249 - S249
  • [9] Haemophagocytic lymphohistiocytosis as a complication of combination anti-PD-1 and anti-CTLA-4 checkpoint inhibitor immunotherapy for metastatic melanoma, and the outcome of rechallenge with single-agent anti-PD-1 immunotherapy
    Holmes, Zachary
    Courtney, Ashling
    Hiong, Alison
    [J]. BMJ CASE REPORTS, 2022, 15 (08)
  • [10] Tumor eradication in a murine model of glioma with vaccination and anti-CTLA-4 but not anti-PD-1
    Field, Cameron S.
    Hunn, Martin K.
    Ferguson, Peter M.
    Yagita, Hideo
    Hermans, Ian F.
    Ancelet, Lindsay R.
    [J]. CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
12345